Literature DB >> 8543204

Autologous platelet concentrate for the treatment of full-thickness macular holes.

A Gaudric1, P Massin, M Paques, P Y Santiago, J E Guez, J F Le Gargasson, O Mundler, L Drouet.   

Abstract

BACKGROUND: To improve the anatomic success rate in the surgery of full-thickness macular holes, we tested, in a prospective pilot study, the effects of autologous platelet concentrate deposited on the macula at the end of surgery.
METHODS: Two consecutive groups of patients were compared. Twenty eyes (group 1, mean symptom duration 11 months) were operated on with injection of an autologous platelet concentrate on the macula after fluid-gas exchange. Another 20 eyes (group 2, mean symptom duration 11 months) were subsequently operated on without autologous platelet concentrate. For all stage 3 holes, posterior hyaloid was detached en bloc at the level of the optic disc. The patient was left supine for 24 h after surgery, and then remained face down for 10 days.
RESULTS: In group 1, 19 cases were an anatomic success, i.e. there was flattening of the retina surrounding the hole and reattachment of the edge of the hole to the retinal pigment epithelium; in 9 cases the hole was even undetectable. Final visual acuity was 0.5 or more in 9 eyes, and 0.4 or more in 14. Visual acuity improved by two lines or more in 17 of the 19 successfully operated eyes. In group 2, only 13 cases were an anatomic success. The functional results for the successfully operated eyes were identical to those of group 1.
CONCLUSION: These results strongly suggested that autologous platelet concentrate could significantly improve the success rate in macular hole surgery and led us to begin a comparative, prospective, randomized trial.

Entities:  

Mesh:

Year:  1995        PMID: 8543204     DOI: 10.1007/bf00404704

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  16 in total

1.  In vivo angiogenesis by platelet-derived wound-healing formula in injured spinal cord.

Authors:  Y Hiraizumi; E E Transfeldt; N Kawahara; J H Sung; D Knighton; V D Fiegel
Journal:  Brain Res Bull       Date:  1993       Impact factor: 4.077

2.  Idiopathic senile macular hole. Its early stages and pathogenesis.

Authors:  J D Gass
Journal:  Arch Ophthalmol       Date:  1988-05

3.  The effect of platelet releasate on wound healing in animal models.

Authors:  G A Ksander; S J Sawamura; Y Ogawa; J Sundsmo; J M McPherson
Journal:  J Am Acad Dermatol       Date:  1990-05       Impact factor: 11.527

4.  Idiopathic macular holes. Observations, stages of formation, and implications for surgical intervention.

Authors:  R N Johnson; J D Gass
Journal:  Ophthalmology       Date:  1988-07       Impact factor: 12.079

5.  Contribution of scanning laser ophthalmoscopy to the functional investigation of subjects with macular holes.

Authors:  J F Le Gargasson; F Rigaudiere; J E Guez; A Gaudric; Y Grall
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

6.  Recognition and removal of the posterior cortical vitreous during vitreoretinal surgery for impending macular hole.

Authors:  C E Mein; H W Flynn
Journal:  Am J Ophthalmol       Date:  1991-05-15       Impact factor: 5.258

7.  Vitreous surgery for macular holes.

Authors:  R T Wendel; A C Patel; N E Kelly; T C Salzano; J W Wells; G D Novack
Journal:  Ophthalmology       Date:  1993-11       Impact factor: 12.079

8.  Pars plana vitrectomy for treatment of stage 2 macular holes.

Authors:  A J Ruby; D F Williams; M G Grand; M A Thomas; T A Meredith; I Boniuk; R J Olk
Journal:  Arch Ophthalmol       Date:  1994-03

9.  Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo.

Authors:  D L Steed; J B Goslen; G A Holloway; J M Malone; T J Bunt; M W Webster
Journal:  Diabetes Care       Date:  1992-11       Impact factor: 19.112

10.  Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study.

Authors:  B M Glaser; R G Michels; B D Kuppermann; R N Sjaarda; R A Pena
Journal:  Ophthalmology       Date:  1992-07       Impact factor: 12.079

View more
  17 in total

1.  Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment.

Authors:  H Hoerauf; H Klüter; E Joachimmeyer; J Roider; C Framme; P Schlenke; H Kirchner; H Lagua
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Late reopening of successfully treated macular holes.

Authors:  M Paques; P Massin; P Y Santiago; A C Spielmann; J F Le Gargasson; A Gaudric
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

Review 3.  [Macular hole. Survey and relevant surgical concepts].

Authors:  S Dithmar
Journal:  Ophthalmologe       Date:  2005-02       Impact factor: 1.059

4.  10 Autologous Hemotherapy.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

5.  Scanning laser ophthalmoscope imaging of fluorescein-labelled blood cells.

Authors:  J F Le Gargasson; M Paques; J E Guez; B Boval; E Vicaut; X Hou; Y Grall; A Gaudric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

6.  Surgical treatment of macular holes with and without the use of autologous platelet-rich plasma.

Authors:  Alexander A Shpak; Dmitry O Shkvorchenko; Eugenia A Krupina
Journal:  Int Ophthalmol       Date:  2021-01-03       Impact factor: 2.031

7.  Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.

Authors:  A Sciscio; A G Casswell
Journal:  Br J Ophthalmol       Date:  2001-02       Impact factor: 4.638

8.  Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.

Authors:  M Minihan; M Goggin; P E Cleary
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

9.  Prevention of visual field defects after macular hole surgery.

Authors:  A B Cullinane; P E Cleary
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

10.  Idiopathic macular hole: analysis of visual outcomes and the use of indocyanine green or brilliant blue for internal limiting membrane peel.

Authors:  Tom H Williamson; Edward Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-22       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.